Opendata, web and dolomites

RabTarget4Metastasis SIGNED

Targeting Rab27A with covalent inhibitors for the treatment of metastatic breast cancer

Total Cost €


EC-Contrib. €






 RabTarget4Metastasis project word cloud

Explore the words cloud of the RabTarget4Metastasis project. It provides you a very rough idea of what is the project "RabTarget4Metastasis" about.

exosome    models    beatson    mortality    evaluation    effectors    obtain    therapeutic    renowned    suggest    covalent    protein    gsk    crick    metastatic    bound    ppis    cells    causes    gtp    compounds    led    vesicles    trigger    engagement    trafficking    hit    physiological    starting    cruk    vivo    accessed    world    derive    offers    fragment    perfect    optimisation    assay    disruption    chemical    irreversible    francis    whilst    discovery    reducing    quantitative    molecular    located    validate    conserved    regulates    occurrence    enhanced    point    preventing    signalling    switch    metastases    tethering    proximity    hits    niche    inactive    undruggable    bind    interfering    prompt    promotion    probes    selective    screen    acts    transport    reactivity    slp2    invasion    efficient    date    residues    melanosome    small    gdp    compound    encouraging    direct    fragments    glutathione    effector    inhibitors    qit    linklab    cancer    cysteines    site    gtpases    metastasis    cycles    active    contribution    mediated    gtpase    rab27a    cascades    potent    interaction    hence   

Project "RabTarget4Metastasis" data sheet

The following table provides information about the project.


Organization address
city: LONDON
postcode: SW7 2AZ

contact info
title: n.a.
name: n.a.
surname: n.a.
function: n.a.
email: n.a.
telephone: n.a.
fax: n.a.

 Coordinator Country United Kingdom [UK]
 Total cost 224˙933 €
 EC max contribution 224˙933 € (100%)
 Programme 1. H2020-EU.1.3.2. (Nurturing excellence by means of cross-border and cross-sector mobility)
 Code Call H2020-MSCA-IF-2019
 Funding Scheme MSCA-IF-EF-ST
 Starting year 2020
 Duration (year-month-day) from 2020-08-01   to  2022-07-31


Take a look of project's partnership.

# participants  country  role  EC contrib. [€] 


 Project objective

Invasion and metastases remain to date the major causes of cancer mortality around the world. Rab27A is a small GTPase that regulates vesicles trafficking and is involved in many physiological processes, e.g. melanosome transport. Being a small GTPase, Rab27A acts as a molecular switch that cycles between an inactive state (GDP bound) and an active state (GTP bound), in which this protein is able to bind to specific effectors to trigger signalling cascades in cells. Current studies suggest a role for Rab27A in exosome-mediated pre-metastatic niche promotion. Hence, interfering with Rab27A PPIs could be effective in reducing and preventing the occurrence of metastasis in cancer. Small GTPases are renowned as challenging targets and have been long considered undruggable, but the unique presence of two non-conserved cysteines in Rab27A offers a perfect starting point for the development of selective covalent inhibitors. These residues are located in the proximity of a major interaction site with a known effector of Rab27A, Slp2, therefore encouraging for targeting PPIs. A screen of covalent fragments based on the recently developed quantitative Irreversible Tethering (qIT) assay has led to the discovery of novel hits with enhanced reactivity for Rab27A against glutathione. The current project aims to (i) obtain potent Rab27A covalent inhibitors by growing hit fragments, and (ii) demonstrate selective Rab27A target engagement in cells, and efficient disruption of the PPIs of Rab27A with its main effectors. Collaboration with the CRUK Beatson Institute will provide direct access to in vivo models to validate the contribution of Rab27A to metastatic development in cancer by use of such chemical probes, whilst state-of-the-art covalent fragment know-how will be accessed for compound optimisation at the Francis Crick Institute/GSK LinkLab, enabling prompt evaluation of the therapeutic potential of optimised lead compounds that will derive from my work.

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "RABTARGET4METASTASIS" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an  email ( and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "RABTARGET4METASTASIS" are provided by the European Opendata Portal: CORDIS opendata.

More projects from the same programme (H2020-EU.1.3.2.)

POMOC (2019)

Charles IV and the power of marvellous objects

Read More  

EPIC (2019)

Evolution of Planktonic Gastropod Calcification

Read More  

NPsVLCD (2019)

Natural Product-Inspired Therapies for Leishmaniasis and Chagas Disease

Read More